BackgroundNo single standard treatment exists for patients with small, node-negative, human epidermal growth factor receptor type 2 (HER2)–positive breast cancers, because most of these patients have been ineligible for the pivotal trials of adjuvant trastuzumab.
The case in point dealt with monetary values. The values are supposed to be non-negative. Actually, they're supposed to be all positive. Some business logic changes later, and financial adjustments (such as credit and waivers) came into the picture.